Rational design of a combination medication for the treatment of obesity
Im concerned that were responding to a market-induced demand rather than a decision based in solid science, Dr
Die Anwendungsdauer richtet sich nach der Art der Beschwerden und/oder dem Verlauf der Erkrankung
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
This would leave the doctor personally on the hook for legal defense and damages
Nie mamy danych o bezpieczestwie, a take nie mamy danych o skutecznoci
